Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Zanini MJ, Dominguez C, Fernandez-Oliva T, Sanchez O, Toda MT, Foraster M, Dadvand P, Llurba E. Urban-related environmental exposures during pregnancy and placental development and preeclampsia: a review. Curr Hypertens Rep. 2020 Sep 3;22(10):81. doi: 10.1007/s11906-020-01088-4
Khellaf M, Le Moine JG, Poitrinal P, Francesconi C, Haddad A, Bierling P, Michel M, Eckert L, Launois R, Godeau B. Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Ann Hematol. 2011 Apr;90(4):441-6. doi: 10.1007/s00277-010-1087-x